csl hong kong aleviate human coagulation factor viii 500iu/von willebrand factor 1000iu complex, powder for injection (50 iu/ml fviii)
csl behring australia pty ltd - von willebrand factor, quantity: 1000 iu; factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - aleviate is indicated for: ? the treatment of bleeding episodes including surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. ? the treatment and prophylaxis of bleeding associated with factor fviii deficiency due to haemophilia a.
dried factor viii type 8y 25iu-ml vial powder and solvent for solution for infusion
bio-product lab, united kingdom - human coagulation factor viii - powder and solvent for solution for infusion - 500 iu,
dried factor viii type 8y 25iu-ml vial powder and solvent for solution for injection
bio-product lab, united kingdom - human coagulation factor viii - powder and solvent for solution for injection - 250 iu,
feiba 500 u, powder and solvent for solution for injection. factor viii inhibitor bypassing activity.
baxter healthcare limited - factor viii inhibitor bypassing fraction 500 u - powder and solvent for solution for injection
emoclot 1000iu/10ml, powder and solvent for solution and infusion + infusion set
kedrion s.p.a loc. ai conti, 55051 castelvecchio pascoli, barga - lucca, italy - factor viii, human - powder and solvent for solution for infusion - factor viii, human 1000 iu - antihemorrhagics
wilate 500, 500 iu vwf/500 iu fviii, powder and solvent for solution for injection
octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - human von, willebrand factor, human coagulation, factor viii - powder and solvent for solution for injection - human von willebrand factor 500 iu human coagulation factor viii 500 iu - antihemorrhagics
dried factor viii, 8y 250iu powder for solution for injection
monofix-vf
csl behring (nz) ltd - factor ix 500 [iu] (human coagulation 100iu/ml when reconstituted with 5ml water for injections) - injection with diluent - 500 iu - active: factor ix 500 [iu] (human coagulation 100iu/ml when reconstituted with 5ml water for injections) excipient: antithrombin iii chloride citric acid monohydrate heparin phosphorus plasma protein fraction sodium water for injection - monofix®-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix®-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix®-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.
monofix-vf human coagulation factor ix 1000iu powder for injection vial and 10 ml diluent vial
csl behring australia pty ltd - factor ix, quantity: 1000 iu - injection, powder for - excipient ingredients: phosphate; plasma proteins; antithrombin iii; heparin sodium; sodium; citrate; chloride - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.
monofix-vf human coagulation factor ix 500iu powder for injection vial and 5ml diluent vial
csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, powder for - excipient ingredients: citrate; heparin sodium; antithrombin iii; sodium; chloride; plasma proteins; phosphate - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.